HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Giovannoni, G. Search for Related Content PubMed PubMed Citation Articles by Giovannoni, G.

Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology.

Strategies to treat and prevent the development of neutralizing anti-interferon-ß antibodies

From the Department of Neuroinflammation, Institute of Neurology, University College London, Queen Square, London, UK.

Address correspondence and reprint requests to Dr. Gavin Giovannoni, Department of Neuroinflammation, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK; e-mail: G.Giovannoni{at}ion.ucl.ac.uk

Up to 35% of people with multiple sclerosis (MS) treated with interferon-ß (IFNß) develop neutralizing anti-IFNß antibodies within 2 years of starting therapy. These antibodies reduce or abolish the biologic effects and clinical efficacy of IFNß. The overall efficacy of IFNß and hence the cost-effectiveness of this treatment would be substantially improved if the development of neutralizing antibodies (NAbs) could be prevented or reversed. Strategies used to prevent or reverse the development of NAbs with other biologic compounds, including improvements in the manufacturing process, immunosuppression, induction of tolerance, and deimmunization, will be reviewed.

This article has been cited by other articles:

				R. Farrell, R. Kapoor, S. Leary, P. Rudge, A. Thompson, D. Miller, and G. Giovannoni Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta Multiple Sclerosis, March 1, 2008; 14(2): 212 - 218. [Abstract] [PDF]

				R. A Farrell and G. Giovannoni Measuring and management of Anti-Interferon Beta Antibodies in subjects with Multiple Sclerosis Multiple Sclerosis, June 1, 2007; 13(5): 567 - 577. [Abstract] [PDF]

				F. Deisenhammer Neutralizing antibody (NAb) assays in multiple sclerosis patients receiving interferon-{beta} therapy Multiple Sclerosis, May 1, 2007; 13(1_suppl): 44 - 48. [Abstract] [PDF]

				C Gneiss, P Tripp, F Reichartseder, R Egg, R Ehling, A Lutterotti, M Khalil, B Kuenz, I Mayringer, M Reindl, et al. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients Multiple Sclerosis, November 1, 2006; 12(6): 731 - 737. [Abstract] [PDF]

				C Ross, K M Clemmesen, P S Sorensen, N Koch-Henriksen, and K Bendtzen Measuring and evaluating interferon b-induced antibodies in patients with multiple sclerosis Multiple Sclerosis, February 1, 2006; 12(1): 39 - 46. [Abstract] [PDF]

				G. Giovannoni and A. Goodman Neutralizing anti-IFN-{beta} antibodies: How much more evidence do we need to use them in practice? Neurology, July 12, 2005; 65(1): 6 - 8. [Full Text] [PDF]

				G. S. Francis, G. P.A. Rice, J. C. Alsop, and for the PRISMS (Prevention of Relapses and Disabil Interferon {beta}-1a in MS: Results following development of neutralizing antibodies in PRISMS Neurology, July 12, 2005; 65(1): 48 - 55. [Abstract] [Full Text] [PDF]